IDEXX Laboratories (IDXX) stock has attracted fresh attention after recent price moves, with a last close of $573 and mixed short term returns that include a gain over the past month but a decline year to date.

Against a backdrop of mixed trading, IDEXX Laboratories has seen its share price recover in the past month, with a 30 day share price return of 8.36% contrasting with a year to date decline of 14.48%. The 1 year total shareholder return of 10.07% points to momentum that has been stronger over the longer horizon than recent price action suggests.

If you are weighing IDEXX alongside other healthcare opportunities, it can be helpful to see what else is attracting interest in similar areas, starting with 40 healthcare AI stocks.

With IDEXX Laboratories posting growing revenue and net income alongside a recent share price pullback, a key question is whether the current level reflects an undervalued quality business or if the market is already pricing in future growth.

Most Popular Narrative: 23.6% Undervalued

Based on the widely followed narrative, IDEXX Laboratories stock is priced at $573 against a modeled fair value of $750.23, which implies a sizeable valuation gap built on specific growth and margin assumptions.

Rapid adoption of innovative diagnostic platforms such as inVue Dx, Catalyst Cortisol, and Cancer Dx are expanding IDEXX's addressable market and boosting recurring consumables demand, which is likely to drive sustained revenue and margin growth as new product usage ramps and menu breadth increases.

Curious what earnings path and profit profile support that fair value for IDEXX Laboratories? The narrative leans on steady expansion in diagnostics, higher recurring revenue intensity, and a premium future earnings multiple tied to those trends.

Result: Fair Value of $750.23 (UNDERVALUED)

However, the bullish IDEXX Laboratories story hinges on clinic visit trends and international adoption. Both of these factors could fall short and weaken the thesis around recurring diagnostics growth.

Another View on IDEXX Laboratories Stock

While the popular narrative treats IDEXX Laboratories stock as 23.6% undervalued against an estimated fair value of $750.23, the current P/E of 41.3x tells a different story. It sits well above the US Medical Equipment industry at 24.6x, peers at 26.3x, and a fair ratio of 28.6x. This points to a valuation that already bakes in a lot of optimism, so it may be worth considering how much upside might remain if sentiment cools.

For a closer look at how that earnings multiple stacks up and what the fair ratio implies about potential re-rating risk, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment split between premium valuation concerns and a quality growth story at IDEXX Laboratories, it may be helpful to review the data yourself promptly and weigh both sides using the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond IDEXX Laboratories?

If IDEXX Laboratories has you thinking about where to allocate capital next, now is the moment to widen your watchlist with other targeted opportunities.

• Spot potential value opportunities early by scanning companies that screen as attractively priced using the 44 high quality undervalued stocks.
• Prioritise resilience by reviewing companies highlighted in the 67 resilient stocks with low risk scores so you are not relying on just one stock for stability.
• Hunt for quality stories flying under the radar by checking the screener containing 20 high quality undiscovered gems before other investors catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.